Medicenna Therapeutics Corp (MDNA : TSX)
Common Stock
$0.36
CAD
+0.00 (%)
Last updated: 2026-07-15
MDNA
Medicenna Therapeutics Corp
WealthAwesomePerformance
1 Day
+0.00%
1 Week
-6.41%
1 Month
-12.05%
YTD
-63.50%
Key Statistics
Market Cap
$33.69M
52W High
$1.97
52W Low
$0.36
P/E Ratio
-
50 Day MA
$0.46
200 Day MA
$0.85
Beta
1.89
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/15/2026 | $0.36 | $0.37 | $0.36 | $0.36 | $0.36 | 18,000 |
| 7/14/2026 | $0.37 | $0.38 | $0.36 | $0.36 | $0.36 | 33,844 |
| 7/13/2026 | $0.36 | $0.37 | $0.36 | $0.37 | $0.37 | 133,223 |
| 7/10/2026 | $0.39 | $0.39 | $0.36 | $0.37 | $0.37 | 64,720 |
| 7/9/2026 | $0.40 | $0.40 | $0.37 | $0.38 | $0.38 | 40,649 |
| 7/8/2026 | $0.40 | $0.40 | $0.39 | $0.39 | $0.39 | 12,995 |
| 7/7/2026 | $0.39 | $0.41 | $0.36 | $0.40 | $0.40 | 186,349 |
| 7/6/2026 | $0.40 | $0.40 | $0.37 | $0.39 | $0.39 | 68,910 |
| 7/3/2026 | $0.40 | $0.40 | $0.38 | $0.40 | $0.40 | 46,093 |
| 7/2/2026 | $0.40 | $0.40 | $0.38 | $0.38 | $0.38 | 91,091 |
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 776.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+776.7% Upside
Current Price
C$0.36
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
44.4%
Annualized
90-Day Vol
70.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.34 | C$0.30 – C$0.40 |
| 60 trading days | C$0.32 | C$0.26 – C$0.40 |
| 90 trading days | C$0.31 | C$0.23 – C$0.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-22.40M
- Profit Margin
- 0.00%
- ROE (TTM)
- -170.64%
- EPS (Diluted)
- -0.22
- Book Value
- 0.03
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About MDNA
Articles Featuring MDNA.TO
Latest articles and analysis covering MDNA.TO
What's Going On With Medicenna Therapeutics Corp Stock Wednesday?
Medicenna Therapeutics Corp has seen its stock decline by 7.59% this week amid ongoing public offering activities and broader market conditions. Investors are advised to consider the implications of these developments.
Why Medicenna Therapeutics Corp stock is sliding today
Medicenna Therapeutics Corp's stock is down 2.70% today, closing at CA$0.36. The decline raises questions about the company's market position and future prospects.
Why Medicenna Therapeutics Corp stock is sliding today
Medicenna Therapeutics Corp is down 3.85% today, closing at CA$0.38. This decline raises concerns about its market position and future prospects amidst ongoing clinical trials.
Why Medicenna Therapeutics Corp stock is sliding today
Medicenna Therapeutics Corp experienced a notable decline in its stock price today, closing at CA$0.38. This 3.85% drop highlights investor caution in the biotech sector, particularly as the company navigates recent public offerings.
Why Medicenna Therapeutics Corp stock is sliding today
Medicenna Therapeutics Corp's stock is down 3.80% today, closing at CA$0.38. Investors are left questioning the company's stability amidst recent public offerings.
Why Medicenna Therapeutics Corp stock is sliding today
Medicenna Therapeutics Corp's stock fell by 3.80% today, closing at CA$0.38. The decline raises questions about the company's market performance amidst a lack of significant news.
Why Medicenna Therapeutics Corp stock is sliding today
Medicenna Therapeutics Corp's stock slid 3.70% in the last trading session, closing at CA$0.39. The lack of significant news leaves investors concerned about the company's future performance.
Why Medicenna Therapeutics Corp stock is rising today
Medicenna Therapeutics Corp's stock rose by 2.44% today, closing at CA$0.42, driven by positive investor sentiment surrounding its clinical advancements.
What to Watch for in Medicenna Therapeutics' Latest Earnings Report
Medicenna Therapeutics is set to report earnings on June 24, 2026, with an EPS estimate of -CA$0.06. Investors will be watching for updates on its clinical programs following a recent public offering.
Why Medicenna Therapeutics Corp stock is rising today
Medicenna Therapeutics Corp's stock rose by 3.61% in the latest session, driven by investor confidence following its recent public offering.
Why Medicenna Therapeutics Corp stock is gaining today
Medicenna Therapeutics Corp's stock gained 1.22% in the last session, closing at CA$0.41. This increase is attributed to investor optimism following recent developments, including a substantial public offering.
Why Medicenna Therapeutics Corp stock is sliding today
Medicenna Therapeutics Corp (MDNA.TO) is experiencing a notable decline, with shares falling 2.33% to CA$0.42. Investors are left questioning the company's trajectory as it navigates through a challenging market environment.
Why Medicenna Therapeutics Corp stock is sliding today
Medicenna Therapeutics Corp stock has slipped 2.22% today, closing at CA$0.44, raising concerns among investors about the company's future.
